Affordable Access

Tolerability and efficacy of the trifunctional antibody removab®(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

Authors
Publisher
BioMed Central Ltd.
Publication Date
Disciplines
  • Ecology
  • Medicine

Abstract

1475-2867-4-S1-S3.fm ral CCANCER CELL ss BioMed Cent TIONALINTERNACancer Cell International Open AcceOral presentation Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study P Wimberger*1, A Burges2, V Gorbounova3, H Sommer4, B Schmalfeldt5, J Pfisterer6, M Lichinitser3, A Makhson7, M Ströhlein8, W Eiermann9, M Biakhov10, V Moiseenko11, A du Bois12 and R Kimmig1 Address: 1Department of Obstetrics and Gynecology, University Hospital, Essen, Germany, 2Department of Obstetrics and Gynecology, University Hospital Munich/Grosshadern, Munich, Germany, 3Research Center for Oncology, Moscow, Russia, 4Department of Obstetrics and Gynecology, University Hospital Munich-City, Munich, Germany, 5Department of Gynecology, University Hospital Technical University, Munich, Germany, 6Department of Obstetrics and Gynecology, University Hospital, Kiel, Germany, 7Moscow Oncology Clinical Hospital, Moscow, Russia, 8Department of Surgery, University Hospital Munich/Grosshadern, Munich, Germany, 9Frauenklinik vom Roten Kreuz, Munich, Germany, 10Central Clinical Hospital of Ministry, Moscow, Russia, 11St. Petersburg Scientific Oncology Institute, St. Petersburg, Russia and 12Department of Gynecology and gynecological Oncology, Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany Email: P Wimberger* - [email protected] * Corresponding author Introduction Malignant ascites in patients with gynecological malig- nancies is associated with poor prognosis and poor qual- ity of life. The bispecific trifunctional antibody removab® (anti-EpCAM x anti-CD3) belongs to a new class of intact antibodies that has been developed for targeted therapy of epithelial tumors. The two binding sites of removab® are directed against epithelial tumor cells (EpCAM+) and T- cells (CD3+) thus recruiting T-cells in the direct environ- ment of tumor cells. Simultaneously, mediated

There are no comments yet on this publication. Be the first to share your thoughts.